Gilead Sciences (GILD) Stock Price, Quote, News & History | Benzinga

Gilead Sciences Inc (GILD) — Q1 FY26 Earnings Call Live coverage with Benzinga. Q1 FY26 Results EPS: $2.03 (est. $1.91) — inline Revenue: $6.96B (est. $6.92B) — inline Reported: 2026-05-07 Recent Quarters Q4 FY25 (2026-02-10): EPS $1.86 vs est $1.83 · Rev $7.92B vs est $7.64B Q3 FY25 (2025-10-30): EPS $2.47 vs est $2.14 · Rev $7.77B vs est $7.46B Q2 FY25 (2025-08-07): EPS $2.01 vs est $1.95 · Rev $7.08B vs est $6.96B Q1 FY25 (2025-04-24): EPS $1.81 vs est $1.76 · Rev $6.67B vs est $6.77B About Gilead Sciences Inc Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics). https://www.gilead.com · Foster City, CA, USA · 17,000 employees Follow Benzinga X: https://x.com/Benzinga Facebook: https://www.facebook.com/Benzinga/ Instagram: https://www.instagram.com/benzinga/ ⚠️ Disclaimer: Investing in financial markets carries risk, and there are no guaranteed returns. All information is for educational purposes only and should not be taken as financial advice. Always do your own research and speak with a qualified financial advisor before making investment decisions. Only invest what you can afford to lose. Past performance does not guarantee future outcomes. #earnings #GILD #stocks #benzinga